{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:49:24Z","timestamp":1793900964440,"version":"4.8.0"},"reference-count":131,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2019,4,3]]},"DOI":"10.1080\/14740338.2019.1594771","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T18:29:07Z","timestamp":1553711347000},"page":"261-271","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":223,"title":["Safety and tolerability of available urate-lowering drugs: a critical review"],"prefix":"10.1080","volume":"18","author":[{"given":"Larysa","family":"Strilchuk","sequence":"first","affiliation":[{"name":",","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-0042","authenticated-orcid":false,"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":false,"given":"Arrigo Fg","family":"Cicero","sequence":"additional","affiliation":[{"name":",","place":["Italy"]},{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3199"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09081"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.10.004"},{"issue":"7","key":"e_1_3_4_6_1","first-page":"1799","article-title":"Diagnosis and management of gout","volume":"599","author":"Pittman JR","year":"1999","unstructured":"Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Phys. 1999;599(7):1799\u20131806.","journal-title":"Am Fam Phys"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.32"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22403"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1755-0"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2015.1099729"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-014-0935-8"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121301"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.9.545"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083071"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1124"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39687"},{"key":"e_1_3_4_18_1","first-page":"607","article-title":"Tranilast, a novel, potential treatment for the chronic management of hyperuricemia in patients with gout, reduces serum uric acid in healthy subjects","volume":"69","author":"Sundy J","year":"2010","unstructured":"Sundy J, Kitt M. Tranilast, a novel, potential treatment for the chronic management of hyperuricemia in patients with gout, reduces serum uric acid in healthy subjects. Ann Rheum Dis. 2010;69:607.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/blood.V106.11.3123.3123","article-title":"Low-dose recombinant urate oxidase (rasburicase) is effective in treating hyperuricemia in patients with hematologic malignancies","volume":"106","author":"Trifilio S","year":"2005","unstructured":"Trifilio S, Evens A, Gordon L, et al. Low-dose recombinant urate oxidase (rasburicase) is effective in treating hyperuricemia in patients with hematologic malignancies. Blood. 2005;106:3123.","journal-title":"Blood"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008317589"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746080-00001"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34488"},{"key":"e_1_3_4_23_1","first-page":"5","article-title":"Treatment of severe drug reactions: stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain PD","year":"2008","unstructured":"Ghislain PD, Roujeau JC. Treatment of severe drug reactions: stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J. 2008;8:5.","journal-title":"Dermatol Online J"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex422"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0084-0"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.06.006"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4848"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2017.03.010"},{"issue":"8","key":"e_1_3_4_30_1","first-page":"e1569","article-title":"Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome: a cause of acalculous cholecystitis?","volume":"9","author":"Waseem H","year":"2017","unstructured":"Waseem H, Inayat F, Abduraimova M, et al. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome: a cause of acalculous cholecystitis? Cureus. 2017;9(8):e1569.","journal-title":"Cureus"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.07.005"},{"issue":"5","key":"e_1_3_4_32_1","article-title":"Allopurinol-induced granulomatous hepatitis: a case report and review of literature","author":"Igbal U","year":"2017","unstructured":"Igbal U, Sidduqui HU, Anwar H, et al. Allopurinol-induced granulomatous hepatitis: a case report and review of literature. J Invest Med High Impact Case Rep. 2017;5(3):2324709617728302. doi: 10.1177\/2324709617728302.","journal-title":"J Invest Med High Impact Case Rep"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12827"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0394632015599705"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.09.038"},{"key":"e_1_3_4_36_1","unstructured":"Allopurinol oral tablets (package insert). Memphis TN: Northstar Rx LLC; 2015."},{"key":"e_1_3_4_37_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2017 Apr 14]. Available from http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-009-0019-z"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(66)90163-8"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1985.00360080174026"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2018.08.012"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.3.776"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2831"},{"key":"e_1_3_4_44_1","unstructured":"Uloric Full Prescribing Information 2009. [cited 2018 Nov 21]. Available from: http:\/\/general.takedapharm.com\/content\/file\/pi.pdf?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&FileTypeCode=ULORICPI"},{"key":"e_1_3_4_45_1","unstructured":"Becker MA Schumacher HR Espinoza L et al. A phase 3 randomized controlled multicenter double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout. Presented at the 2008 Annual Scientific Meeting of the American College of Rheumatology; October 24\u201329 2008; San Francisco. Available from: http:\/\/acr.confex.com\/acr\/2008\/webprogram\/Paper3414.html"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710895"},{"key":"e_1_3_4_48_1","first-page":"1","article-title":"The future of febuxostat after the cardiovascular safety of febuzostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial: who CARES?","volume":"4","author":"Katsiki N","year":"2018","unstructured":"Katsiki N, Borghi C. The future of febuxostat after the cardiovascular safety of febuzostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial: who CARES? Expert Opin Pharmacother. 2018;4:1\u20134.","journal-title":"Expert Opin Pharmacother"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph11020051"},{"key":"e_1_3_4_50_1","first-page":"983","article-title":"Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis","volume":"20","author":"Borghi C","year":"2016","unstructured":"Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2016;20:983\u2013992.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182247b45"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H121"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3474-8"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12620"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.10.003"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13177"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-17-0438"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00227.2008"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31815acb10"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13702"},{"key":"e_1_3_4_61_1","unstructured":"Probenecid Oral. [cited 2018 Nov 21]. Available from: http:\/\/www.medscape.com\/druginfo\/dosage?drugid=8697&drugname=probenecid+Oral&monotype=default"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1955.00250070099012"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S6048"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1965.tb12257.x"},{"key":"e_1_3_4_65_1","first-page":"208","article-title":"Probenecid induced immune hemolytic anemia","volume":"13","author":"Kickler T","year":"1986","unstructured":"Kickler T, Buck S, Ness P, et al. Probenecid induced immune hemolytic anemia. J Rheumatol. 1986;13:208\u2013209.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl798"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090090046018"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-39"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.114671"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2013.11.004"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2108-2112.2003"},{"key":"e_1_3_4_72_1","unstructured":"Probenecid oral tablets (package insert). New Castle DE: Marlex Pharmaceuticals Inc; 2012."},{"key":"e_1_3_4_73_1","first-page":"33","article-title":"Treatment of gonorrhea in pregnancy","volume":"81","author":"Cavenee MR","year":"1993","unstructured":"Cavenee MR, Farris JR, Spalding TR, et al. Treatment of gonorrhea in pregnancy. Obstet Gynecol. 1993;81:33\u201338.","journal-title":"Obstet Gynecol"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e32835ddad2"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831080-00002"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00710.x"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197714050-00002"},{"issue":"34","key":"e_1_3_4_78_1","first-page":"549","article-title":"Gout-current diagnosis and treatment","volume":"106","author":"Tausche AK","year":"2009","unstructured":"Tausche AK, Jansen TL, Schr\u00f6der HE, et al. Gout-current diagnosis and treatment. Deutsches \u00c4rzteblatt Int. 2009;106(34\u201335):549\u2013555.","journal-title":"Deutsches \u00c4rzteblatt Int"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1586-y"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1995.tb00102.x"},{"issue":"11","key":"e_1_3_4_81_1","first-page":"CD010457","article-title":"Uricosuric medications for chronic gout","author":"Kydd A","year":"2014","unstructured":"Kydd A, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014;(11):CD010457. doi: 10.1002\/14651858.CD010457.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"e_1_3_4_83_1","first-page":"263720","article-title":"Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients","author":"Azevedo VF","year":"2014","unstructured":"Azevedo VF, Grachinski Buiar P, Giovanella LH, et al. Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol. 2014;2014:263720. doi: 10.1155\/2014\/263720.","journal-title":"Int J Rheumatol"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1401609"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1107-x"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.324"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.323"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex350"},{"key":"e_1_3_4_89_1","unstructured":"Zurampic (lesinurad) prescribing information. Wilmington (DE): AstraZeneca; 2015."},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex433"},{"key":"e_1_3_4_91_1","first-page":"106002801876210","article-title":"Lesinurad: a novel agent for management of chronic gout","volume":"1","author":"Haber SL","year":"2018","unstructured":"Haber SL, Fente G, Fenton SN, et al. Lesinurad: a novel agent for management of chronic gout. Ann Pharmacother. 2018;1:1060028018762103.","journal-title":"Ann Pharmacother"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00716361"},{"issue":"6","key":"e_1_3_4_93_1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0090-9556(25)06638-3","article-title":"Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites","volume":"23","author":"He M","year":"1995","unstructured":"He M, Kunze KL, Trager WF. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. Drug Metab Dispos. 1995;23(6):659\u2013663.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(00)00216-3"},{"issue":"5","key":"e_1_3_4_95_1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0090-9556(25)08257-1","article-title":"Influence of cimetidine, sulfinpyrazone, and cigarette smoking on theobromine metabolism in man","volume":"13","author":"Miners JO","year":"1985","unstructured":"Miners JO, Attwood J, Wing LM, et al. Influence of cimetidine, sulfinpyrazone, and cigarette smoking on theobromine metabolism in man. Drug Metab Dispos. 1985;13(5):598\u2013601.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(83)80010-0"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9629(15)40340-4"},{"issue":"2","key":"e_1_3_4_98_1","first-page":"55","article-title":"Acute interstitial nephritis and kidney failure requiring dialysis after sulfinpyrazone therapy","volume":"11","author":"Prior C","year":"1984","unstructured":"Prior C, Kirchmair H. Acute interstitial nephritis and kidney failure requiring dialysis after sulfinpyrazone therapy. Acta Med Austriaca. 1984;11(2):55\u201359.","journal-title":"Acta Med Austriaca"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.30"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2674"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.4.433"},{"issue":"8","key":"e_1_3_4_102_1","first-page":"CD006945","article-title":"Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer","volume":"8","author":"Cheuk DK","year":"2014","unstructured":"Cheuk DK, Chiang AK, Chan GC, et al. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2014;8(8):CD006945.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.10.1595"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886312666170111151246"},{"key":"e_1_3_4_105_1","unstructured":"FDA\/Center for Drug Evaluation and Research OoC. Highlights of prescribing information.[Jan;2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103946s5083lbl.pdf.2009"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S103864"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1836-8"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0255-7"},{"key":"e_1_3_4_109_1","first-page":"35","article-title":"Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions","volume":"147","author":"Pea F","year":"2005","unstructured":"Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol. 2005;147:35\u201346.","journal-title":"Contrib Nephrol"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4318"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201795"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000200"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1396-8"},{"key":"e_1_3_4_114_1","unstructured":"Bahrt KM Yeo AE Howson TL et al. Post-marketing safety surveillance data reveals patterns of use for pegloticase in refractory gout. ACR\/ARHP Annual Meeting Washington DC 2012; Abstract."},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4497"},{"key":"e_1_3_4_116_1","unstructured":"Krystexxa [package insert]. Glendale WI: Crealta Pharmaceuticals LLC; 2016."},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q593"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1616"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S1743"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S140658"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1538003"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0652-2"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1119"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000584"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.463"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X16646703"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39684"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161062"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.291"},{"issue":"8","key":"e_1_3_4_130_1","first-page":"1051","article-title":"Five cases of drug-induced liver injury by tranilast","volume":"102","author":"Jimbo R","year":"2005","unstructured":"Jimbo R, Yoshioka A, Takahashi Y, et al. Five cases of drug-induced liver injury by tranilast. [Article in Japanese]. Nihon Shokakibyo Gakkai Zasshi. 2005;102(8):1051\u20131054.","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1998.tb02488.x"},{"issue":"1","key":"e_1_3_4_132_1","first-page":"45","article-title":"Eosinophilic cystitis induced by tranilast: a case report","volume":"44","author":"Sakai N","year":"1998","unstructured":"Sakai N, Yamada T, Murayama T. Eosinophilic cystitis induced by tranilast: a case report. [Article in Japanese]. Hinyokika Kiyo. 1998;44(1): 45\u201347.","journal-title":"Hinyokika Kiyo"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1990.tb01622.x"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2019.1594771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:44:17Z","timestamp":1772743457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2019.1594771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,3]]}},"alternative-id":["10.1080\/14740338.2019.1594771"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2019.1594771","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}